Get started
Author

Michael D. Linn

Observed names: MICHAEL D. LINN, Michael D. Línn, Michael Linn, Michael Van Linn
OpenAlex ID: A5034137887
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
2013 · Christian Tovar, Bradford Graves, et al. · Cancer Research · 281
Linguistics for Teachers
1993 · Linda Miller Cleary, Michael Linn · Medical Entomology and Zoology · 14
Informant Selection in Dialectology
1983 · Michael D. Linn · American Speech · 14
Black Rhetorical Patterns and the Teaching of Composition
1975 · Michael D. Linn · College Composition and Communication · 12
Black and White Adolescent and Preadolescent Attitudes Toward Black English
1982 · Michael D. Linn, Gene Piche · Research in the Teaching of English · 8
Black and White Adolescent and Preadolescent Attitudes Toward Black English
1986 · Michael D. Linn, Gene Piché · Elsevier eBooks · 2
A Reanalysis of the Dialect Boundaries of the Linguistic Atlas of the Upper Midwest
1990 · Michael D. Linn · Journal of English Linguistics · 1
Project Occult: the Ordered Computer Collation of Unprepared Literary Texts
1974 · Michael D. Linn · Resources for American Literary Study · 1
Design and Illicit Manufacture of Synthetic Drugs
2025 · Michael Van Linn, Christine Herdman, et al. · Drug and Alcohol Dependence
Supplementary Figures 1 - 3, Tables 1 - 2 from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
PDF
Supplementary Figures 1 - 3, Tables 1 - 2 from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
Data from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
Data from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2023 · Brian Higgins, Kelli Glenn, et al.
Data from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
Supplementary Figures 1 - 5 from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
2023 · Christian Tovar, Bradford Graves, et al.
PDF
Supplementary Table 1 from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
2023 · Christian Tovar, Bradford Graves, et al.
Supplementary Methods and Materials from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
Supplementary Figure 2 from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
PDF
Supplementary Figure 1 from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
PDF
Supplementary Figure 1 from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
Supplementary Figure 2 from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
Supplementary Methods and Materials from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2023 · Leopoldo Luistro, Wei He, et al.
PDF
Supplementary Figure Legends from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
2023 · Christian Tovar, Bradford Graves, et al.
PDF
Supplementary Methods from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
2023 · Christian Tovar, Bradford Graves, et al.
Supplementary Figures 1 - 5 from MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
2023 · Christian Tovar, Bradford Graves, et al.
Works count: 44
Citation count: 333
H-index: 5
I10-index: 4
Year
Topic
Type